MEDIA RELEASE

PARTNERSHIP AGREEMENT with DAISY’S EYE CANCER FUND and AURORA
AURORA TO DONATE CLINICAL & EDUCATIONAL COMMUNICATION TOOLS TO FUND CO-FOUNDED BY DR. BRENDA GALLIE

MONTREAL (CANADA), December 10, 2009 – Aurora Interactive Ltd., a world leader in digital pathology communications announced today that the company has signed a Memorandum of Understanding (MOU) with Daisy’s Eye Cancer Fund (DECF) to facilitate the analysis of images of the childhood eye cancer retinoblastoma in Kenya and enable online consultation between national and international colleagues.

Retinoblastoma is a curable cancer. In developed countries, 97% of affected children are cured, many retaining useful vision. However, the majority of the world’s children affected with retinoblastoma live in less economically developed countries, where less than 20% survive. Without prompt specialist medical care, including histopathological analysis to detect risk of tumour spread, retinoblastoma quickly extends beyond the confines of the eye, to the eye socket, brain or bone marrow, with very poor chance of cure.

Dr. Brenda Gallie, Director of The Hospital for Sick Children’s Retinoblastoma Program and International Medical Director of DECF, stated that: “Timely and accurate pathology is key for survival of children with retinoblastoma. This important contribution from Aurora Interactive will enable Kenyan doctors to achieve the best possible care and ultimately save the lives of children with retinoblastoma.”

Together with the Kenyan National Retinoblastoma Strategy group, DECF identified the University of Nairobi as a centre with the capacity to develop into a national Retinoblastoma Collaborative Laboratory Service. Towards building this program, Aurora Interactive Ltd. will grant to DECF free licenses and ongoing software training for mScope Clinical and Education Suites, which will facilitate collaborative consultation between healthcare professionals involved in the management of retinoblastoma patients, both nationally and internationally. The MOU also includes the undertaking from Aurora to facilitate continuing retinoblastoma medical education by enabling online course material submission in Kenya with review by national and international specialists.

Mr. Pierre Le Fèvre, President and Chief Executive Officer of Aurora declared that: “We are extremely happy to support the remarkable work initiated by Dr. Gallie and the Kenyan National Retinoblastoma Strategy group, to improve the chance of survival for children with retinoblastoma.”

About Aurora Interactive Aurora’s mission is to facilitate better patient outcomes, helping members of the medical community achieve their full potential by eliminating the learning, diagnostic and collaborative restrictions posed by time and space.www.aurorainteractive.com

Aurora Interactive has developed the leading web based software platform (mScope) for simplification, productivity and ease of communications. mScope’s universal web viewer has collaborative tools to view medical slides and images anytime, anywhere, regardless of file format. The software has three applications to aid digital pathology web based communications needs, mScope Education, mScope Clinical, and mScope Universal Viewer.

About Daisy’s Eye Cancer Fund Daisy’s Eye Cancer Fund (DECF) is a global charity whose mission is to improve care for children with retinoblastoma eye cancer, and to provide support for their families. DECF is a special fund within The Hospital for Sick Children Foundation in Canada, a registered charity in the UK, and a registered NGO in Kenya. In partnership with a dedicated team of professionals and lay people in Kenya, this organization is developing a ground-breaking management system for retinoblastoma that will serve as a prototype for the rest of Africa.

* Source: Report from the First Kenyan National Retinoblastoma Strategy Meeting, September 2008

For further information, please contact:

Jacques C. Gagnon
JCG Communications
(514) 713-7303
jcgagnon@jcgcom.ca

Dr. Brenda Gallie
University Health Network
416-946-2323
gallie@attglobal.net